interleukin-1beta (163-171) has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Z; Chen, S; Cui, Y; Ding, K; Guo, Y; Han, Y; Li, P; Li, Q; Li, R; Shi, Z; Wang, J; Wang, Z; Wen, J; Xiao, X; Xu, G; Zhan, X; Zhao, X; Zhou, Y | 1 |
1 other study(ies) available for interleukin-1beta (163-171) and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Inhibitory effects and mechanisms of the anti-covid-19 traditional Chinese prescription, Keguan-1, on acute lung injury.
Topics: Acute Lung Injury; Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Capsules; Chemokine CXCL2; Coix; COVID-19; Drugs, Chinese Herbal; Forsythia; Interleukin-1beta; Interleukin-6; Lonicera; Lung; Mice; Mortality; Morus; Peptide Fragments; Prunus armeniaca; Respiration; SARS-CoV-2; Treatment Outcome; Tumor Necrosis Factor-alpha | 2022 |